{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:18:20Z","timestamp":1767961100199,"version":"3.49.0"},"reference-count":28,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Traditional surgeries for benign prostatic hyperplasia (BPH), such as transurethral resection of the prostate (TURP), carry risks including sexual dysfunction and extended recovery. EchoLaser transperineal laser ablation (TPLA) offers a minimally invasive alternative with potential benefits in preserving sexual function and reducing recovery time. This exploratory study evaluated the safety and efficacy of EchoLaser TPLA for the treatment of prostate-related voiding symptoms. Methods: This retrospective, single-center study enrolled seven patients with lower urinary tract symptoms due to BPH. TPLA was performed under local anesthesia, and follow-up was conducted at 1, 3, 6, and 12 months. The primary outcome was measured by the International Prostate Symptom Score (IPSS). Secondary outcomes included PSA levels, prostate and transition zone (TZ) volume, Qmax, post-void residual (PVR) volume, quality of life (QoL) score, Sexual Health Inventory for Men (SHIM) score, and Male Sexual Health Questionnaire to assess for ejaculatory dysfunction (MSHQ-EjD) score. Results: Statistically significant improvements in IPSS, Qmax, PVR, and QoL relative to baseline were observed at 1 month post-treatment, and these improvements remained significant throughout the 12-month follow-up period. Post-treatment reductions in PV and TZ volume were statistically significant at 6 months; while PV was further reduced at 12 months, this change lacked statistical significance. No statistically significant post-treatment changes were observed in SHIM, MSHQ-EjD 3-Item or Bother scores, or PSA. Mean pain score on the 10-point visual analog scale for procedural pain was 2.14 \u00b1 0.69. Conclusions: Although limited by a lack of generalizability, our findings are consistent with previous studies that have shown EchoLaser TPLA to be a safe and effective in-office treatment for prostate-related voiding symptoms, with minimal discomfort and negligible impact on sexual function. Further studies with larger cohorts and extended follow-up are needed.<\/jats:p>","DOI":"10.3390\/jcm15020540","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T10:35:52Z","timestamp":1767954952000},"page":"540","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Case Series on the Efficacy and Safety of Transperineal Laser Ablation for Benign Prostatic Hyperplasia"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1520-101X","authenticated-orcid":false,"given":"Malone R.","family":"Locke","sequence":"first","affiliation":[{"name":"Department of Urology, University of Arizona, Tucson, AZ 85724, USA"},{"name":"Columbia Campus, University of South Carolina School of Medicine, Columbia, SC 29209, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald Russell","family":"Locke","sequence":"additional","affiliation":[{"name":"Vantage Urologic Institute, Ocala, FL 34481, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/01.ju.0000155709.37840.fe","article-title":"Urologic diseases in America project: Benign prostatic hyperplasia","volume":"173","author":"Wei","year":"2005","journal-title":"J. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7984","DOI":"10.1038\/s41598-017-06628-8","article-title":"The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis","volume":"7","author":"Lee","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1038\/s41598-025-90229-3","article-title":"Comprehensive analysis of the global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021","volume":"15","author":"Chen","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Singh, M., Singh, S., Khurana, N., Pandey, N., Bhatt, V.R., Thomas, S., Saikia, T.J., Vali, S.V., and Kimnuntluangi, J. (2024). Histopathological evaluation of prostate lesions: A comprehensive approach. Prostate Diseases\u2014Management Strategies and Emerging Technologies, IntechOpen.","DOI":"10.5772\/intechopen.1006651"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e129749","DOI":"10.1172\/jci.insight.129749","article-title":"Genomic analysis of benign prostatic hyperplasia implicates cellular relandscaping in disease pathogenesis","volume":"4","author":"Middleton","year":"2019","journal-title":"JCI Insight"},{"key":"ref_6","first-page":"806\u2212817","article-title":"Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I\u2014Initial work-up and medical management","volume":"206","author":"Lerner","year":"2021","journal-title":"J. Urol."},{"key":"ref_7","unstructured":"Cornu, J.N., Gacci, M., Hashim, H., Herrmann, T.R.W., Malde, S., Netsch, C., De Nunzio, C., Rieken, M., Sakalis, V., and Tutolo, M. (2025, April 17). EAU Guidelines on Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS). Available online: https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Non-Neurogenic-Male-LUTS-2024.pdf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/JU.0000000000003698","article-title":"Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA Guideline amendment 2023","volume":"211","author":"Sandhu","year":"2023","journal-title":"J. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Tafuri, A., Panunzio, A., De Carlo, F., Luperto, E., Di Cosmo, F., Cavaliere, A., Rizzo, M., Tian, Z., Shakir, A., and De Mitri, R. (2023). Transperineal laser ablation for benign prostatic enlargement: A systematic review and pooled analysis of pilot studies. J. Clin. Med., 12.","DOI":"10.3390\/jcm12051860"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Alberti, A., Lo Re, M., Nicoletti, R., Polverino, P., Cadenar, A., Ciaralli, E., Solazzi, F., Giustozzi, B., Sessa, F., and Rivetti, A. (Prostate Cancer Prostatic Dis., 2025). Transperineal laser ablation in the management of benign prostatic hyperplasia: An updated systematic review and pooled analysis, Prostate Cancer Prostatic Dis., ahead of print.","DOI":"10.1038\/s41391-025-00952-1"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bju.16008","article-title":"Ejaculatory function following transperineal laser ablation vs TURP for benign prostatic obstruction: A randomized trial","volume":"132","author":"Bertolo","year":"2023","journal-title":"BJU Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1007\/s11255-023-03717-8","article-title":"Transurethral resection of the prostate (TURP) versus transperineal laser ablation (TPLA) due to benign prostatic hyperplasia (BPH): Prospective and comparative study","volume":"55","author":"Canat","year":"2023","journal-title":"Int. Urol. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.diii.2025.04.001","article-title":"Laser-focused ablative therapy for prostate cancer and benign prostatic hyperplasia: A review of current applications and future directions","volume":"106","author":"Cornud","year":"2025","journal-title":"Diagn. Interv. Imaging"},{"key":"ref_14","first-page":"10960\u221210968","article-title":"Five-year outcomes for Aquablation therapy compared to TURP: Results from a double-blind, randomized trial in men with LUTS due to BPH","volume":"29","author":"Gilling","year":"2022","journal-title":"Can. J. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"143\u2212153","DOI":"10.1097\/JU.0000000000003483","article-title":"Aquablation therapy in large prostates (80\u2013150 mL) for lower urinary tract symptoms due to benign prostatic hyperplasia: Final WATER II 5-year clinical trial results","volume":"210","author":"Bhojani","year":"2023","journal-title":"J. Urol."},{"key":"ref_16","first-page":"8802\u22128813","article-title":"Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study","volume":"24","author":"Roehrborn","year":"2017","journal-title":"Can. J. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"715\u2212724","DOI":"10.1097\/JU.0000000000001778","article-title":"Final 5-year outcomes of the multicenter randomized sham-controlled trial of Rez\u016bm water vapour thermal therapy for treatment of moderate-to-severe lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"206","author":"McVary","year":"2021","journal-title":"J. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1549\u22121557","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association","volume":"148","author":"Barry","year":"1992","journal-title":"J. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/sj.ijir.3900472","article-title":"Development and evaluation of an abridged, 5-item version of the International Index of Erectile Dysfunction (IIEF-5) as a diagnostic tool for erectile dysfunction","volume":"11","author":"Rosen","year":"1999","journal-title":"Int. J. Impot. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.urology.2007.02.036","article-title":"Development and validation of four-item version of Male Sexual Health Questionnaire to assess ejaculatory function","volume":"69","author":"Rosen","year":"2007","journal-title":"Urology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00345-023-04322-1","article-title":"Ultrasound-guided SoracteLite\u2122 transperineal laser ablation (TPLA) of the prostate for the treatment of symptomatic benign prostatic hyperplasia (BPH): A prospective single-center experience","volume":"41","author":"Licari","year":"2023","journal-title":"World J. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Pacini, M., Zucchi, A., Salonia, A., Sollazzi, E., Macri, G., Volterrani, R., Bini, V., Antonov, P., Ivanov, A., and d\u2019Arma, A. (Prostate Cancer Prostatic Dis., 2025). Short term results after minimally invasive treatments for benign prostatic enlargement: The first randomized trial comparing transperineal laser ablation and water vapor ablation, Prostate Cancer Prostatic Dis., ahead of print.","DOI":"10.1038\/s41391-025-00972-x"},{"key":"ref_23","first-page":"e00007","article-title":"Office-based transperineal laser ablation for benign prostatic hyperplasia under local anesthesia: 2-year results from a dose range confirmatory trial","volume":"2","author":"Bianco","year":"2024","journal-title":"J. Urol. Open Plus"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Sessa, F., Polverino, P., and Moscardi, L. (2024). Transperineal laser ablation of prostate (TPLA\u2122). Diseases of Prostate\u2014Management Strategies and Emerging Technologies, Intech Open.","DOI":"10.5772\/intechopen.1006649"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"17562872231198634","DOI":"10.1177\/17562872231198634","article-title":"Transperineal laser ablation as a new minimally invasive surgical therapy for benign prostatic hyperplasia: A systematic review of existing literature","volume":"15","author":"Tzelves","year":"2023","journal-title":"Ther. Adv. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/jsxmed\/qdaf150","article-title":"Preserving erectile and ejaculatory function in patients undergoing minimally invasive techniques: The first randomized clinical trial comparing convective water vapor ablation and transperineal laser ablation","volume":"22","author":"Zucchi","year":"2025","journal-title":"J. Sex. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jvir.2024.04.023","article-title":"Transperineal laser ablation of the prostate for symptomatic benign prostatic hyperplasia: Long-term follow-up in 40 patients","volume":"35","author":"Patelli","year":"2024","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"471\u2212478","DOI":"10.23736\/S2724-6051.23.05270-9","article-title":"Three years outcomes of transperineal laser ablation of the prostate","volume":"75","author":"Minafra","year":"2023","journal-title":"Minerva Urol. Nephrol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/2\/540\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T10:47:00Z","timestamp":1767955620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/2\/540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["jcm15020540"],"URL":"https:\/\/doi.org\/10.3390\/jcm15020540","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]}}}